Home > Insider Trading > Filing (0001445064-15-000032)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1567892	Mallinckrodt Plc	MNK	Pharmaceutical Preparations (2834)	981088325

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1540412	Mark Trudeau	675 Mcdonnell Blvd. Hazelwood MO 63042	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Ordinary Shares	Disposition	2015-02-01	3,440	$105.99	157,197	No	4	F	Direct
Ordinary Shares	Acquisiton	2015-02-02	17,904	$37.85	175,101	No	4	M	Direct
Ordinary Shares	Disposition	2015-02-02	6,625	$105.51	168,476	No	4	S	Direct
Ordinary Shares	Disposition	2015-02-02	4,200	$106.31	164,276	No	4	S	Direct
Ordinary Shares	Disposition	2015-02-02	1,100	$107.17	163,176	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	F	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Share Options (Right to Buy)	Acquisiton	2015-02-02	17,904	$0.00	17,904	$37.85

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
17,904	2013-02-01	2022-01-31	No	4	M	Direct

Footnotes

The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 4, 2014.
This represents the weighted average price paid for the shares. The shares were sold at prices ranging from $104.90 to $105.87, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc, or a shareholder of Mallinckrodt plc complete information regarding the number of shares sold at each price within the ranges set forth in footnotes (2) - (4) to this Form 4.
This represents the weighted average price paid for the shares. The shares were sold at prices ranging from $105.91 to $106.89, inclusive.
This represents the weighted average price paid for the shares. The shares were sold at prices ranging from $106.92 to $107.50, inclusive.
The options representing rights to purchase 71,616 ordinary shares became exercisable in four equal installments beginning on February 1, 2013, which is the first anniversary from the date of the grant.